antiretrovirals

Fixed-Dose Bictegravir, Emtricitabine, Tenofovir Alafenamide Is Efficacious HIV-1 Treatment Option

Fixed-Dose Bictegravir, Emtricitabine, Tenofovir Alafenamide Is Efficacious HIV-1 Treatment Option

By

The fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide might provide a safe and efficacious option for ongoing treatment of HIV-1 infection

Switch to Dolutegravir Regimen Improves Lipid Profile in HIV+ Patients

Switch to Dolutegravir Regimen Improves Lipid Profile in HIV+ Patients

By

Immediate and deferred switching from a boosted protease inhibitor to a dolutegravir regimen in HIV + patients is found to be highly efficacious.

Generic HIV Medicines: Boon or Bust?

Generic HIV Medicines: Boon or Bust?

By

Generic antiretroviral agents have had a dramatic effect on outcomes in developing nations, and their availability in developed countries is rapidly expanding as more brand-name drugs are coming off patent. But unique challenges surrounding their use remain.

Single-Tablet HIV Regimen Improves Retention in Care and Virologic Suppression

Single-Tablet HIV Regimen Improves Retention in Care and Virologic Suppression

By

Investigators assessed adherence to antiretroviral therapy, retention in care, and virologic outcomes in patients receiving once-daily single-tablet and multiple-tablet antiretroviral therapy regimens.

Emerging Technologies to Manage Antiretroviral Therapy Adherence

Emerging Technologies to Manage Antiretroviral Therapy Adherence

By

The rapidly developing landscape of antiretroviral therapy adherence monitoring has great potential for clinical application, but cost-effectiveness and feasibility studies are needed to define the appropriate roles for these new technologies.

Worse Cognitive Outcomes Associated With CMV Antibodies Following ART for HIV

Worse Cognitive Outcomes Associated With CMV Antibodies Following ART for HIV

By

Investigators sought to determine the association between antiretroviral therapy and cytomegalovirus infection in individuals with HIV, as well as the potential impact of both on neurocognitive performance.

Increased Risk for Abdominal Obesity Found in People Living With HIV

Increased Risk for Abdominal Obesity Found in People Living With HIV

By

The Copenhagen Co-morbidity in HIV Infection (COCOMO) study assessed the association between risk factors for cardiovascular disease and HIV infection.

Rising Incidence of Diabetes in Adults With HIV on Antiretroviral Therapy

Rising Incidence of Diabetes in Adults With HIV on Antiretroviral Therapy

By

More research is needed to better capture the interplay between prediabetes/diabetes and antiretroviral therapy in people with HIV.

Alcohol Use in HIV Not Associated With Short-Term CD4 Cell Count Decline

Alcohol Use in HIV Not Associated With Short-Term CD4 Cell Count Decline

By

Unhealthy alcohol use does not appear to have a short-term direct biological effect on CD4 cell count.

Prognostic Value of Plasma JC Virus-DNA in Progressive Multifocal Leukoencephalopathy

Prognostic Value of Plasma JC Virus-DNA in Progressive Multifocal Leukoencephalopathy

By

Polyomavirus JC-DNA assessment in plasma samples might complement progressive multifocal leukoencephalopathy diagnosis, especially when cerebrospinal fluid (CSF) is unavailable or polyomavirus JC-DNA is not detectable in CSF.

Mortality in HIV-Infected Children Predicted by Urine TB Lipoarabinomannan

Mortality in HIV-Infected Children Predicted by Urine TB Lipoarabinomannan

By

Benefits of urine lipoarabinomannan include its rapid point-of-care platform, low cost, and readily accessible sample type.

HIV Care Continuum: Effects of Depression, Alcohol Use on Early Retention in ART

HIV Care Continuum: Effects of Depression, Alcohol Use on Early Retention in ART

By

Mental health at the time of antiretroviral therapy initiation indicates early effect on the HIV care continuum.

More Evidence That Early Diagnosis of HIV and Early ART Are Beneficial

More Evidence That Early Diagnosis of HIV and Early ART Are Beneficial

By

Since early ART limits HIV reservoir size and preserves central memory CD4 cells, patients treated from primary HIV infection with low HIV-DNA levels might be good candidates for future HIV cure strategies.

Acquired HIV Drug Resistance Unlikely With Immediate ART Initiation

Acquired HIV Drug Resistance Unlikely With Immediate ART Initiation

By

In high-income countries, the need for second-line treatments due to the development of acquired drug resistance will increase only slightly under the new ART initiation guidelines.

Higher CKD Risk in HIV With Combination Tenofovir, Boosted Protease Inhibitor

Higher CKD Risk in HIV With Combination Tenofovir, Boosted Protease Inhibitor

By

In patients living with HIV receiving TDF with a ritonavir-boosted protease inhibitor, the risk of CKD may be increased.

Pausing ART to Identify Biomarkers for HIV RNA Rebound: Safety and Ethical Considerations

Pausing ART to Identify Biomarkers for HIV RNA Rebound: Safety and Ethical Considerations

By

Dr Gianella Weibel talks with Dr Li and Dr Dubé, investigators of a new study from the AIDS Clinical Trials Group, which uses an intensively monitored antiretroviral pause to identify changes in HIV reservoirs after anti-HIV medications are stopped.

No Change in Brain Structure, Cognitive Performance in Aviremic HIV

No Change in Brain Structure, Cognitive Performance in Aviremic HIV

By

Study suggests that early initiation of combination antiretroviral therapy and full viral suppression may preserve long-term brain health.

New ART Recommendations for Pregnant Women With HIV

New ART Recommendations for Pregnant Women With HIV

By

The GRADE framework recommendations provide guidance for combination treatment regimens based on 2 systemic reviews, patient considerations, fetal outcomes, and practical issues.

Abacavir ART Does Not Increase Risk for Myocardial Infarction or CVD

Abacavir ART Does Not Increase Risk for Myocardial Infarction or CVD

By

Abacavir-containing antiretroviral therapy does not appear to confer an increased risk for myocardial infarction or coronary artery disease.

Dyslipidemia in Children With HIV Started on Antiretroviral Therapy

Dyslipidemia in Children With HIV Started on Antiretroviral Therapy

By

Researchers aim to identify changes in blood lipid profiles among children with HIV after 12 months of using antiretroviral therapy.

Why Patients Discontinue ART— and What You Can Do to Stop It

Why Patients Discontinue ART— and What You Can Do to Stop It

By

Learn more about when stopping antiretroviral therapy (ART) may be necessary, why patients discontinue ART, predicting viral suppression, and predicting and encouraging adherence.

Adverse Birth Outcomes Affected by Specific Antiretroviral Regimen in Pregnancy

Adverse Birth Outcomes Affected by Specific Antiretroviral Regimen in Pregnancy

By

The combination of tenofovir disoproxil fumarate, emtricitabine, and efavirenz was associated with the lowest risk of adverse birth outcome compared to other ART treatments.

DHA Reduces Fasting Triglycerides in HIV With Hypertriglyceridemia

DHA Reduces Fasting Triglycerides in HIV With Hypertriglyceridemia

By

Researchers aimed to reduce incidence of hypertriglyceridemia in people with HIV undergoing cART.

Risk for Secondary Tumors After Kaposi Sarcoma Has Changed in the HAART Era

Risk for Secondary Tumors After Kaposi Sarcoma Has Changed in the HAART Era

By

Tumors, such as acute lymphocytic leukemia, cancer of the tongue, and cancer of the penis, are becoming more common in the HAART era compared with the pre-HAART era.

Point-of-Care Testing of HIV-Exposed Infants Improves Linkage to Care

Point-of-Care Testing of HIV-Exposed Infants Improves Linkage to Care

By

Point-of-care testing of HIV-exposed infants at birth yielded results comparable to the standard of care laboratory-based testing and reduced time to result and time to antiretroviral therapy initiation.

Amphotericin and Flucytosine Safe, Effective for HIV-Associated Cryptococcal Meningitis

Amphotericin and Flucytosine Safe, Effective for HIV-Associated Cryptococcal Meningitis

By

One-week amphotericin plus flucytosine was found to have comparable efficacy and safety profiles as the standard of care, 2-weeks amphotericin-based therapy, for treatment of HIV-associated cryptococcal meningitis in African patients.

Child Maintains HIV Remission Without ART Since 2008

Child Maintains HIV Remission Without ART Since 2008

By

A child who was diagnosed with HIV at 1 month and received early treatment has suppressed the virus without anti-HIV therapy for 8.5 years.

New WHO Guidelines for Managing Pretreatment HIV Drug Resistance

New WHO Guidelines for Managing Pretreatment HIV Drug Resistance

By

New WHO guidelines address the issue of how to manage pretreatment human immunodeficiency virus drug resistance (HIVDR) in countries where the prevalence of HIVDR is 10% or higher.

Long-Acting Injectable Antiretrovirals for HIV Effective and Safe

Long-Acting Injectable Antiretrovirals for HIV Effective and Safe

By

The combination of long-acting intramuscular cabotegravir plus rilpivirine was demonstrated to be as effective as 3-drug daily oral ART for maintaining viral suppression of HIV-1 for up to 96 weeks in the LATTE-2 phase 2b study.

ART and PrEP: How Technological Advances Can Improve Adherence

ART and PrEP: How Technological Advances Can Improve Adherence

By

Several technological advances have been developed to improve adherence to antiretroviral and preexposure prophylaxis therapy.

Sign Up for Free e-newsletters